Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine.

Jun HJ, Appleman VA, Wu HJ, Rose CM, Pineda JJ, Yeo AT, Delcuze B, Lee C, Gyuris A, Zhu H, Woolfenden S, Bronisz A, Nakano I, Chiocca EA, Bronson RT, Ligon KL, Sarkaria JN, Gygi SP, Michor F, Mitchison TJ, Charest A.

Nat Commun. 2018 Aug 6;9(1):3116. doi: 10.1038/s41467-018-05036-4.

2.

Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma.

Yeo AT, Charest A.

J Cell Biochem. 2017 Sep;118(9):2516-2527. doi: 10.1002/jcb.25948. Epub 2017 May 3. Review.

3.

Adaptive Significance of ERα Splice Variants in Killifish (Fundulus heteroclitus) Resident in an Estrogenic Environment.

Cotter KA, Nacci D, Champlin D, Yeo AT, Gilmore TD, Callard GV.

Endocrinology. 2016 Jun;157(6):2294-308. doi: 10.1210/en.2016-1052. Epub 2016 Apr 12.

PMID:
27070100
4.

Inhibition of Oncogenic Transcription Factor REL by the Natural Product Derivative Calafianin Monomer 101 Induces Proliferation Arrest and Apoptosis in Human B-Lymphoma Cell Lines.

Yeo AT, Chennamadhavuni S, Whitty A, Porco JA Jr, Gilmore TD.

Molecules. 2015 Apr 23;20(5):7474-94. doi: 10.3390/molecules20057474.

5.

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.

Faber AC, Farago AF, Costa C, Dastur A, Gomez-Caraballo M, Robbins R, Wagner BL, Rideout WM 3rd, Jakubik CT, Ham J, Edelman EJ, Ebi H, Yeo AT, Hata AN, Song Y, Patel NU, March RJ, Tam AT, Milano RJ, Boisvert JL, Hicks MA, Elmiligy S, Malstrom SE, Rivera MN, Harada H, Windle BE, Ramaswamy S, Benes CH, Jacks T, Engelman JA.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1288-96. doi: 10.1073/pnas.1411848112. Epub 2015 Mar 3.

6.

Disulfide-mediated stabilization of the IκB kinase binding domain of NF-κB essential modulator (NEMO).

Zhou L, Yeo AT, Ballarano C, Weber U, Allen KN, Gilmore TD, Whitty A.

Biochemistry. 2014 Dec 23;53(50):7929-44. doi: 10.1021/bi500920n. Epub 2014 Dec 8.

7.

mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.

Faber AC, Coffee EM, Costa C, Dastur A, Ebi H, Hata AN, Yeo AT, Edelman EJ, Song Y, Tam AT, Boisvert JL, Milano RJ, Roper J, Kodack DP, Jain RK, Corcoran RB, Rivera MN, Ramaswamy S, Hung KE, Benes CH, Engelman JA.

Cancer Discov. 2014 Jan;4(1):42-52. doi: 10.1158/2159-8290.CD-13-0315. Epub 2013 Oct 25.

8.

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, Drew L, Saeh JC, Crosby K, Sequist LV, Iafrate AJ, Engelman JA.

Sci Transl Med. 2012 Feb 8;4(120):120ra17. doi: 10.1126/scitranslmed.3003316. Epub 2012 Jan 25.

9.

Bcl-XL, but not Bcl-2, can protect human B-lymphoma cell lines from parthenolide-induced apoptosis.

Yeo AT, Porco JA Jr, Gilmore TD.

Cancer Lett. 2012 May 1;318(1):53-60. doi: 10.1016/j.canlet.2011.11.035. Epub 2011 Dec 6.

Supplemental Content

Support Center